Jump to content
  • Sign Up
Sign in to follow this  
Admin

Secukinumab (Cosentyx)

Recommended Posts

consentyx.png

 Secukinumab has been in clinical trial since 2017. A recent update from Healio states, "Patients treated with secukinumab for papulopustular rosacea saw significant improvements in quality of life and reduction of severity markers, according to a study presented at the American Academy of Dermatology virtual meeting." [1]

Cosentyx is the brand name for secukinumab, which "is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A." [2] 

"Secukinumab is a recombinant fully human IgG1/kappa monoclonal antibody and is manufactured in Chinese hamster ovary cells." [2]

The clinical trial was small with only 23 participants over sixteen weeks.  

End Notes 

[1] Clinical Trials, Third Post, RRDi 

[2]  Secukinumab, Wikipedia

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

×
×
  • Create New...